R. McIntyre has received research grants from private industries or non-profit funds, such as the Canadian Institutes of Health Research, China National Natural Research Foundation, Lundbeck, Shire, and Stanley Medical Research Institute; during the last two years, R. McIntyre has also received speaker/consultation fees from Allergan, Janssen-Ortho, Lundbeck, Neuralstem, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, and Takeda. T. Suppes has reported in the last 36 months grants from Merck, National Institute of Health, National Institute of Mental Health, National Institute on Drug Abuse, Palo Alto Health Sciences, Pathways Genomics, Stanley Medical Research Institute, VA Cooperative Studies Program, and VA OR&D PRIME Care; consulting fees from Allergan, Inc. and Sunovion Pharmaceuticals Inc.; honoraria from CMEology, Global Medical Education, and Medscape Education; royalties from Jones and Bartlett, Hogrefe Publishing and Wolters Kluwer Health (UpToDate); and travel reimbursement from CMEology, Global Medication Education, and Sunovion Pharmaceuticals, Inc. W. Earley is an employee of Allergan, and shareholder of Allergan, AstraZeneca, and Eli Lilly. M. Patel is an employee of Allergan. Stephen M. Stahl, MD, PhD, is an Adjunct Professor of Psychiatry at the University of California San Diego, Honorary Visiting Senior Fellow at the University of Cambridge, UK and Director of Psychopharmacology for California Department of State Hospitals. Over the past 36 months (January 2016–March 2019), Dr. Stahl has served as a consultant to Acadia, Adamas, Alkermes, Allergan, Arbor Pharmaceuticals, AstraZeneca, Avanir, Axovant, Axsome, Biogen, Biomarin, Biopharma, Celgene, Concert, ClearView, DepoMed, Dey, EnVivo, Ferring, Forest, Forum, Genomind, Innovative Science Solutions, Intra-Cellular Therapies, Janssen, Jazz, Lilly, Lundbeck, Merck, Neos, Novartis, Noveida, Orexigen, Otsuka, PamLabs, Perrigo, Pfizer, Pierre Fabre, Reviva, Servier, Shire, Sprout, Sunovion, Taisho, Takeda, Taliaz, Teva, Tonix, Trius, Vanda and Vifopharma; He has been a board member to RCT Logic and Genomind; he has served on speakers bureaus for Acadia, Astra Zeneca, Dey Pharma, EnVivo, Eli Lilly, Forum, Genentech, Janssen, Lundbeck, Merck, Otsuka, PamLabs, Pfizer Israel, Servier, Sunovion and Takeda, and he has received research and/or grant support from Acadia, Alkermes, AssureX, Astra Zeneca, Arbor Pharmaceuticals, Avanir, Axovant, Biogen, Braeburn Pharmaceuticals, BristolMyer Squibb, Celgene, CeNeRx, Cephalon, Dey, Eli Lilly, EnVivo, Forest, Forum, GenOmind, Glaxo Smith Kline, Intra-Cellular Therapies, ISSWSH, Janssen, JayMac, Jazz, Lundbeck, Merck, Mylan, Neurocrine, Neuronetics, Novartis, Otsuka, PamLabs, Pfizer, Reviva, Roche, Sepracor, Servier, Shire, Sprout, Sunovion, TMS NeuroHealth Centers, Takeda, Teva, Tonix, Vanda, Valeant and Wyeth.
All authors met the ICMJE authorship criteria and are entirely responsible for the scientific content for this paper. Neither honoraria nor payments were made for authorship.
1.Grande, I, Berk, M, Birmaher, B, Vieta, E. Bipolar disorder. Lancet. 2016; 387(10027): 1561–1572.
2.Miller, S, Dell’Osso, B, Ketter, TA. The prevalence and burden of bipolar depression. J Affect Disord. 2014; 169(Suppl 1): S3–11.
3.Kupka, RW, Altshuler, LL, Nolen, WA, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord. 2007; 9(5): 531–535.
4.Kessler, RC, Akiskal, HS, Ames, M, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry. 2006; 163(9): 1561–1568.
5.Simon, GE, Ludman, EJ, Unutzer, J, Operskalski, BH, Bauer, MS. Severity of mood symptoms and work productivity in people treated for bipolar disorder. Bipolar Disord. 2008; 10(6): 718–725.
6.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
7.Swann, AC, Lafer, B, Perugi, G, et al. Bipolar mixed states: an international society for bipolar disorders task force report of symptom structure, course of illness, and diagnosis. Am J Psychiatry. 2013; 170(1): 31–42.
8.Rosenblat, JD, McIntyre, RS. Treatment of mixed features in bipolar disorder. CNS Spectr. 2017; 22(2): 141–146.
9.Fornaro, M, Stubbs, B, De Berardis, D, et al. Atypical antipsychotics in the treatment of acute bipolar depression with mixed features: a systematic review and exploratory meta-analysis of placebo-controlled clinical trials. Int J Mol Sci. 2016; 17(2): 241.
10.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
11.McIntyre, RS, Soczynska, JK, Cha, DS, et al. The prevalence and illness characteristics of DSM-5-defined "mixed feature specifier" in adults with major depressive disorder and bipolar disorder: results from the International Mood Disorders Collaborative Project. J Affect Disord. 2015; 172:259–264.
12.Miller, S, Suppes, T, Mintz, J, et al. Mixed depression in bipolar disorder: prevalence rate and clinical correlates during naturalistic follow-up in the Stanley bipolar network. Am J Psychiatry. 2016; 173(10): 1015–1023.
13.Perugi, G, Angst, J, Azorin, JM, et al. Mixed features in patients with a major depressive episode: the BRIDGE-II-MIX study. J Clin Psychiatry. 2015; 76(3): e351–e358.
14.Goldberg, JF. Mixed depression: a farewell to differential diagnosis? J Clin Psychiatry. 2015; 76(3): e378–e380.
15.Koukopoulos, A, Sani, G. DSM-5 criteria for depression with mixed features: a farewell to mixed depression. Acta Psychiatr Scand. 2014; 129(1): 4–16.
16.Goldberg, JF, Perlis, RH, Bowden, CL, et al. Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry. 2009; 166(2): 173–181.
17.Betzler, F, Stover, LA, Sterzer, P, Kohler, S. Mixed states in bipolar disorder – changes in DSM-5 and current treatment recommendations. Int J Psychiatry Clin Pract. 2017; 21(4): 244–258.
18.Pacchiarotti, I, Bond, DJ, Baldessarini, RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013; 170(11): 1249–1262.
19.Fornaro, M, Anastasia, A, Novello, S, et al. Incidence, prevalence and clinical correlates of antidepressant-emergent mania in bipolar depression: a systematic review and meta-analysis. Bipolar Disord. 2018; 20(3): 195–227.
20.Post, RM. The impact of bipolar depression. J Clin Psychiatry. 2005; 66 Suppl 5:5–10.
21.Leggio, GM, Salomone, S, Bucolo, C, et al. Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. Eur J Pharmacol. 2013; 719(1-3): 25–33.
22.Celada, P, Puig, M, Amargos-Bosch, M, Adell, A, Artigas, F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci. 2004; 29(4): 252–265.
23.Stahl, SM, Morrissette, DA, Faedda, G, et al. Guidelines for the recognition and management of mixed depression. CNS Spectr. 2017; 22(2): 203–219.
24.Durgam, S, Earley, W, Lipschitz, A, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2016; 173(3): 271–281.
25.Earley, W, Burgess, M, Rekeda, L, et al. Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study. Am J Psychiatry. 2019; 176(6): 439–448.
26.Earley, W, Burgess, M, Khan, B, et al. Treatment of bipolar I depression with cariprazine: a randomized double-blind placebo-controlled trial. Poster presented at: Psych Congress; October 25-28, 2018; Orlando, FL.
27.Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23(1): 56–62.
28.Hamilton, M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967; 6(4): 278–296.
29.Miller, IW, Bishop, S, Norman, WH, Maddever, H. The modified Hamilton rating scale for depression: reliability and validity. Psychiatry Res. 1985; 14(2): 131–142.
30.Guy, W. Clinical Global Impressions. In: Guy, W, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch; 1976:217–222.
31.Young, RC, Biggs, JT, Ziegler, VE, Meyer, DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978; 133:429–435.
32.Posner, K, Brown, GK, Stanley, B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011; 168(12): 1266–1277.
33.Montgomery, SA, Asberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134:382–389.
34.Frye, MA, Helleman, G, McElroy, SL, et al. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry. 2009; 166(2): 164–172.
35.Tohen, M, Kanba, S, McIntyre, RS, Fujikoshi, S, Katagiri, H. Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features. J Affect Disord. 2014; 164:57–62.
36.McIntyre, RS, Cucchiaro, J, Pikalov, A, Kroger, H, Loebel, A. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry. 2015; 76(4): 398–405.
37.Patkar, A, Gilmer, W, Pae, CU, et al. A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PLoS One. 2012; 7(4): e34757.
38.Judd, LL, Schettler, PJ, Akiskal, H, et al. Prevalence and clinical significance of subsyndromal manic symptoms, including irritability and psychomotor agitation, during bipolar major depressive episodes. J Affect Disord. 2012; 138(3): 440–448.
39.McIntyre, RS. Mixed features and mixed states in psychiatry: from calculus to geometry. CNS Spectr. 2017; 22(2): 116–117.
40.Girgis, RR, Slifstein, M, D’Souza, D, et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology (Berl). 2016; 233(19-20): 3503–3512.
41.Stahl, SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th ed. Cambridge, New York: Cambridge University Press; 2013.
42.Nakajima, S, Gerretsen, P, Takeuchi, H, et al. The potential role of dopamine D(3) receptor neurotransmission in cognition. Eur Neuropsychopharmacol. 2013; 23(8): 799–813.
43.Niitsu, T, Fabbri, C, Serretti, A. Predictors of switch from depression to mania in bipolar disorder. J Psychiatr Res. 2015; 66–67:45–53.